Court bans Krka's marketing of esomeprazole in Austria
This article was originally published in Scrip
Executive Summary
The commercial court in Vienna has imposed a temporary injunction on marketing any product containing esomeprazole (AstraZeneca's treatment for stomach acid-related diseases Nexium) enantiomers with optical purity of more than 99.8% by Krka in Austria after AstraZeneca alleged that its patent EP 1020461 had been infringed.